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Introduction {#s0005}
============

Percutaneous nephrolithotomy (PCNL) is a minimally invasive treatment method for urinary tract stone disease. Today PCNL has virtually replaced open stone surgery, as it has significant advantages, e.g. relatively short length of hospital stay (LOS), lower treatment costs, less loss of labour, and a minimal surgical incision. However, there are various complications of PCNL, as with any other surgical procedure. Probable underlying causes that may be associated with these complications have been examined in many studies. Many patients who have previously undergone ESWL, later present with a recurrent stone in the same kidney and need PCNL [@b0005]. ESWL has the potential for serious side-effects and complications, although it has been shown in large series to be a reliable and an effective method [@b0010], [@b0015]. ESWL-related complications can occur acutely, as well as later. The economic burden of kidney stones includes both direct and indirect costs; the latter including decreased or lost work productivity. In 2005, the Urological Disease in America Project analysed the direct and indirect costs of stone disease using medical and pharmacy claims of 25 large USA employers covering \>300,000 beneficiaries aged 18--64 years for the calendar year 2000 [@b0015]. In the present study, we evaluated the effects of previous unsuccessful ESWL treatments (failed disintegration of stones or failed clearance of stones, not recurrences) on the performance and outcome of PCNL.

Patients and methods {#s0010}
====================

Of the PCNL procedures performed in our Urology Clinic at Tepecik Training and Research Hospital Turkey, between January 2009 and October 2014, 393 patients had similar stone burdens (cumulative stone burden \>600 mm^2^), as well as number of accesses and were included in this retrospective study. Stone size was evaluated by CT. Patients were divided into two groups: Group 1, comprised 143 (36.3%) patients who underwent ESWL (failed disintegration of stones or failed clearance of stones) within 1 year prior to PCNL (to standardised all patients); Group 2, comprised 250 (63.7%) patients who had no ESWL. Haemoglobin (Hb) levels and stone-free rates before and after PCNL were evaluated and compared. The demographic details of the groups are shown in [Table 1](#t0005){ref-type="table"}.Table 1Demographic data and characteristics of the kidney stones.VariableGroup 1Group 2*P*Number of patients (%)143 (36.3)250 (63.6)Age, years, mean45.646.10.98BMI, kg/m^2^, mean28.127.80.87Male/female, *n*80/63140/1100.13Stone size, mm^2^, mean4254600.078Side, right/left, *n*63/80120/1300.69

Complete blood count, serum creatinine, sodium, potassium, liver function tests, urine analysis, urine culture and antibiogram, and coagulation tests were performed preoperatively for each patient. In all patients a complete blood count was repeated 2 h after PCNL. Anti-aggregant or anticoagulant treatments were discontinued for ≥7 days before PCNL. We excluded patients that had a bleeding tendency or abnormal coagulogram. All patients were evaluated by CT preoperatively. All procedures were conducted according to the regulations of the Local Ethics Committee.

Patients with a cumulative stone burden (for multiple stones, total area) of \>600 mm^2^, multiple access, and incomplete data were excluded from the study. The stone size (for one stone = length × weight) was assessed as the surface area and calculated according to European Association of Urology guidelines [@b0020].

The PCNL procedure {#s0015}
------------------

The PCNLs were performed under general anaesthesia. The patients were placed in lithotomy position and an open-ended 6-F ureteric catheter placed using a 22-F cystoscope, with the correct placement of the catheter into the renal collecting system confirmed by fluoroscopy. The ureteric catheter was stabilised using silk ties on to the urethral 16-F Foley catheter to prevent displacement during turning of the patient from a supine to prone position. The patient was prone positioned and the anaesthetist supervised the head and neck. The renal collecting system was imaged using retrograde contrast medium diluted with saline (∼1:1).

After the introduction of the 18-G needle under fluoroscopy, the safety guidewire was inserted through the needle into the renal collecting system (generally the lower calyx), preferably into the ureter and renal parenchymal dilatation was performed up to 30 F, although not in all patients. The 'bulls-eye' and 'triangulation' techniques were used for puncture. In our clinic, Amplatz dilators are generally preferred because they are considered to be safer and more effective. For an intercostal approach, the anaesthetist ensured safe entry, by means of expiration. In patients who developed perioperative haemorrhage, blood transfusion was given if needed after assessing the perioperative haematocrit results and haemodynamic assessment by the anaesthetist. Blood transfusions were also given to patients whenever appropriate according to their postoperative complete blood count. During the operation, the guidewire was introduced through the ureteric catheter and then removed via the ureteric catheter. When the operation was completed, a re-entry malecot catheter was usually placed in such a way that it fitted into the renal pelvis. For those patients with haemorrhage, the nephrostomy tube was maintained clamped, until they were transferred to a bed. Generally for all the patients, the urinary catheter was removed on the first postoperative day. The nephrostomy tube of stable patients without haematuria was also removed on the first day. A JJ ureteric stent was inserted in patients with long-term leakage, i.e. at 2 days after PCNL.

Patient demographics, stone characteristics, operative findings, success rate, need for auxiliary treatments, and complications were documented in detail and compared in each group. Data were expressed as mean and standard deviation (SD). The Statistical Package for the Social Sciences for Windows (SPSS® version 20.0; IBM Corporation, NY, USA) was used for statistical analysis. Numbers, means, percentages, and intervals were assessed. Numbers and percentages were compared using the chi-square test. Before the comparison of mean values, the values were evaluated for homogeneity. Homogenously distributed values were compared using the Student's *t*-test and heterogeneously distributed values were compared using the Mann--Whitney *U*-test. Additionally, univariate and multivariate analyses were used to compare the effect of ESWL history and PCNL outcomes. A *P* \< 0.05 was considered to indicate statistical significance.

Results {#s0020}
=======

The mean (SD) age of the patients was 45.9 (14.1) years. Of the 393 patients included in the study, 173 (44%) were women and 220 (56%) were men. The mean (range) patient age in Group 1 was 45.6 (2--67) years and was 46.1 (19--66) years in Group 2. The mean (range) stone burden was 425 (220--440) mm^2^ in Group 1 and 460 (230--445) mm^2^ in Group 2. There were no differences between the groups for age, sex, weight, and stone laterality. [Table 1](#t0005){ref-type="table"} lists the patient demographics and stone characteristics. For all the patients included in the study, intervention was achieved by a single access. Residual stones were identified in 96 (24.4%) patients in the postoperative period. The stone-free rate was 74.8% (107 patients) in Group 1 and 76% (190 patients) in Group 2. In all, 10 patients were taking an anti-aggregant before surgery. Blood transfusion was needed in16 (4%) patients; these patients' had a mean (range) body mass index (BMI) of 27.5 (25--31) kg/m^2^ and two patients used an anti-aggregant before surgery. The mean (range) amount of blood given to patients undergoing blood transfusion was 1.68 (1--4) units. At the end of the PCNL, re-entry malecot catheters were used in 309 (78.6%) patients and a 16-F nelaton urethral catheter in 84 (21.3%) patients. The mean (range) time to nephrostomy tube withdrawal was 2.88 (1--5) days and the mean (range) LOS was 3 (1--17) days.

Six patients were taking an anti-aggregant before surgery in Group 1. In Group 1 (ESWL-treated patients), residual stones were identified in 36 (25.1%) patients and 17 units of blood were transfused in 11 (7.6%); these patients' had a mean (range) BMI of 27.1 (26--30.3) kg/m^2^ and one patient used an anti-aggregant before surgery. The mean (range) LOS of ESWL-treated patients was 3 (1--12) days and the mean (SD) time to nephrostomy tube removal was 2.8 (1.4) days ([Table 2](#t0010){ref-type="table"}). Of patients who had had no ESWL (Group 2), residual stones were identified in 60 (24%) and 10 units of blood were transfused in five (2%). The mean (range) LOS stay was 3 (1--17) days and the mean (SD) time to nephrostomy tube withdrawal was 2.8 (0.8) days. There was no statistically significant differences between the groups for LOS, nephrostomy tube removal time, and the presence of residual stones (*P* = 0.957, *P* = 0.961, *P* = 0.51, respectively; [Table 2](#t0010){ref-type="table"}). The mean (SD, range) Hb level decrease in Group 1 was 3.4 (2.8, 0.2--6.1) g/dL and in Group 2 was 1.1 (3.2, 0.1--5.1) g/dL (*P* = 0.01). In all, 11 (7.6%) patients in Group 1 and five (2%) in Group 2 needed blood transfusions, with most patients receiving 1 unit of blood. When both groups were evaluated for preoperative and postoperative Hb drop and the rate of blood transfusion, these were significantly more common in patients that had had ESWL treatment (both *P* = 0.01; [Table 3](#t0015){ref-type="table"}).Table 2Perioperative and postoperative findings.VariableGroup 1 (*n* = 143)Group 2 (*n* = 250)*P*Mean (range) Fluoroscopy time, min2.3 (1--10)2.4 (1--12)0.81 Operative time, min83.4 (35--170)82.7 (31--160)0.77Final stone-free rate, *n* (%)107 (74.8)190 (76)0.51Mean (range) Hospitalisation time, days3 (1--12)3 (1--17)0.95 Duration of nephrostomy, days2.8 (1--5)2.8 (1--6)0.98Table 3PCNL complications in the studied groups.ComplicationGroup 1 (*n* = 143)Group 2 (*n* = 250)*PN* (%):Prolonged tract leakage3 (2)4 (1.6)0.058Fever4 (2.7)7 (2.8)0.062UTI8 (5.5)11 (4.4)0.079Pleural effusion1 (0.6)1 (0.4)0.97Regional cellulitis--3 (1.2)\<0.01Sepsis2 (1.3)4 (1.6)0.068Required blood transfusion11 (7.6)5 (2)0.01Mean Hb decline, g/dL3.41.10.01

As shown in [Table 3](#t0015){ref-type="table"}, there was no difference between the groups for either intraoperative or postoperative major and minor complications. There were no deaths. Most of the complications were pain, bleeding, urine leakage after removal of the nephrostomy tube, and postoperative fever. Pleural effusion, as a major complication, was seen in one patient in Group 1 and one patient in Group 2; they were treated conservatively. Postoperative major infections, such as pyelonephritis or sepsis, developed in two patients in Group 1 and four patients in Group 2. A regional cellulitis developed on the needle access area in three patients in Group 2, and second generation cephalosporin was administered. Septic shock, damage to neighbouring organs, and bowel perforation did not occur in any of our patients.

Discussion {#s0025}
==========

Urinary tract stone disease constitutes a substantial part of daily urological practice. The rate of developing kidney stones in one's lifetime has been reported to be ∼10% [@b0025]. Current treatment options for kidney stones include ESWL, PCNL, ureteroscopy (URS), open surgery, and laparoscopy. PCNL is a minimally invasive surgical method and today it has almost replaced open surgery. PCNL has significant advantages, e.g. short LOS, lower treatment costs, less labour loss. However, it has various complications as well, just as any other surgical procedure. Many studies have evaluated various cases associated with these complications. The objective of the present study was to evaluate the efficacy and safety of PCNL in patients with a history of ESWL by comparing them with primary PCNL patients.

In one of the first series on this subject published in 1985, Segura et al. [@b0030] examined 1000 PCNL cases and reported a major complication rate of 3.2%. In that study, intraoperative bleeding was the most common complication occurring in six (0.6%) patients and resulted in termination of the operation as necessary. In addition, six (0.6%) patients who developed arteriovenous fistula had embolisation, and one patient underwent nephrectomy due to excessive postoperative bleeding, but no deaths were reported.

In their study conducted in 1987, Lee et al. [@b0035] classified complications due to PCNL as major (death, bleeding requiring surgical intervention, sepsis, urinary tract injury and neighbouring organs injury) or minor (postoperative fever, bleeding requiring transfusion, extravasation, dislocation of nephrostomy, pneumonia and long-term wetting). Bleeding is one of the most significant complications of percutaneous entry of the upper urinary tract. The reported blood transfusion rate for percutaneous nephrostomy procedures is 0.5--4% [@b0040]. In addition, the need for blood transfusion can rise from 6% up to 20% when opening the percutaneous tract with wider calibrations and with intrarenal manipulations during PCNL [@b0045], [@b0050]. The factors associated with bleeding include: multiple entries, supracostal entry, dilatation of the tract, tract dilatation with different procedures other than with balloon dilatation, prolonged operation time, and renal pelvis perforation [@b0040]. However, most bleeds are from the renal parenchyma, which are not imperative in many cases. In cases of increased stone burden, especially staghorn stones, increased bleeding is likely during PCNL. Factors that may cause severe bleeding, such as arteriovenous fistula or pseudoaneurysm, are seen in \<0.5% of PCNL cases [@b0055]. Bleeding that requires treatment can occur in ∼ 1% of percutaneous operations [@b0060], [@b0065]. The effect of ESWL on bleeding during PCNL is controversial.

Many medical centres are concerned about the adverse effects of ESWL on tissues [@b0070]. Clinical and experimental studies have shown that this treatment might have severe, acute and chronic effects on the kidney and its peripheral tissues [@b0075], [@b0080], [@b0085]. Acute renal changes after ESWL emerge as a significant decrease in effective renal plasma flow and GFR in the first 24--48 h [@b0090]. Possible chronic changes include an increase in blood pressure, decrease in renal function, and increased recurrence of developing kidney stone.

Renal damage in ESWL is known to be primarily a vascular lesion. Acute and chronic renal disorders may appear after ESWL due to the development of severe damage at the microvascular level and at the interstitium in nephrons [@b0095], [@b0100]. Renal parenchymal damage due to ESWL has been detected by MRI in 85% of patients [@b0105], [@b0110]. Parenchymal damage may range from a small parenchymal lesion to the development of manifest haematoma. Theoretically these lesions may cause arterial hypertension, as they do in renal trauma cases.

The effects of lithotripsy on the kidney have been tested in animal models. Although the primary studies conducted by Chaussy et al. [@b0115] showed a lack of pathological variations in dogs' kidneys after lithotripsy, subsequent research showed that pathological changes may develop [@b0120]. Thin-wall vessels are sensitive to shockwave damage. The haemorrhage extent is directly related to the kilo-voltage used and number of shocks of the prescribed wave [@b0125]. Some studies have referred to the effects of lithotripsy on renal tubules and glomerulus cells. The appearance of detrimental effects after intense ESWL applications has been confirmed in many studies [@b0130], [@b0135]. Stoller et al. [@b0140] retrospectively reviewed their cases and showed that previous ESWL history had no effect on bleeding in subsequent PCNLs. However, brittle tissue and white membranes in damaged calyxes and the pelvicalyceal system were observed in another study, as the results of nephroscopy of the PCNL attempt following a failed ESWL [@b0145]. They additionally expressed that, fragmented and scattered stones in the calyx were likely to indicate an additional percutaneous access. However, the rates of success and complications were found to be similar in both patient groups, those who had undergone ESWL and those who had not. In the study by Resorlu et al. [@b0150] in 2010, the effect of PCNL on bleeding after open surgery and ESWL were evaluated, but no statistically significant difference was found between the groups. Mungan et al. [@b0155] evaluated patients who underwent PCNL after ESWL and found no significant statistical difference between the groups for residual kidney stones and blood transfusions. Although success appears to be affected by the scar tissue that is likely to develop, we think that thickening of scar tissue and Gerota's fascia can be successfully overcome by Amplatz dilators. High success and low blood transfusion rates can be achieved by the effective use of imaging systems, the quality of the instruments used, developing technology and increasing surgical experience.

In our present study, unlike other published studies, PCNL after ESWL treatment was found to increase the amount of bleeding and the need for blood transfusion. We enrolled patients who had stone burdens of \<600 mm^2^ and accessed with one attempt. Therefore, we think that our ESWL-treated patients more accurately represent the potential for blood loss during PCNL.

Although fragmentation and easy collection of stones after ESWL has played a role in the success of the procedure, in the longer term it has been found that the fragmented stones tend to get stuck in the collecting system due to scar formation, and hence traction applied to the kidney, as well as the difficulty of the procedure, can cause bleeding and this may lead to residual stones being left behind. Searching for a large number of broken stone pieces as a result of ESWL can extend the operation time, hence may lead to variations in bleeding and residual rates [@b0155]. In the present study, ESWL treatment was shown not to affect the stone-free rates of patients with similar kidney stone burdens. In addition, the other variables that we examined such as operation time, incidence of postoperative complications and LOS were shown not to be affected by ESWL pretreatment as well.

As for the limitations of our present study, we should mention that it had small number of patients enrolled and it was a retrospective study. However, unlike other published studies showing that ESWL has no effect on bleeding during PCNL, our present study has shown that ESWL increases perioperative bleeding and the need for transfusion. So our present study will incite reconsideration of the debate on this issue. Therefore, this point should be taken into consideration when examining our present data. Large-scale studies are needed to evaluate the earlier effects of the ESWL and its effects on operational success.

Conclusion {#s0030}
==========

Many patients who undergo PCNL have undergone ESWL treatment beforehand. The renal side-effects of ESWL are well known, the duration of which varies between studies. In the present study, we found that previous ESWL had an effect on bleeding during the PCNL procedure. The PCNL procedure can be applied with similar success rates after ESWL, but close attention should be paid to bleeding.
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